Through application of Coegin Pharma's fundamental research, and in international cooperation with recognized researchers, cPLA₂α has been identified as a relevant therapeutic target for a number of inflammatory diseases and cancers, including actinic keratosis, basal cell carcinoma, leukemia, triple-negative breast cancer and chronic kidney disease.
Actinic keratosis is sun damage to the skin caused by excessive sun exposure during the course of life. It is a very common precursor to skin cancer.
Basal cell carcinoma is the most common form of skin cancer and the most common of all cancers.
Leukemia is an umbrella term that includes acute and chronic lymphoblastic leukemia (ALL, CLL) and acute and chronic myeloid leukemia (AML, CML).
Triple-negative breast cancer is an aggressive form of the disease, characterized by the absence of estrogen and progesterone receptors and not involving overexpression of human epidermal growth factor 2 (HER2).
Chronic kidney disease (CKD) is the culmination of a series of diseases that compromise the renal function and may ultimately lead to kidney failure and death.